KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $66.2 million.

  • Takeda Pharmaceutical's Long-Term Investments fell 2070.28% to $66.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $66.2 million, marking a year-over-year decrease of 2070.28%. This contributed to the annual value of $70.9 million for FY2025, which is 9699.9% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Long-Term Investments of $66.2 million as of Q4 2025, which was down 2070.28% from $60.5 million recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Long-Term Investments peaked at $2.3 billion during Q1 2024, and registered a low of $60.5 million during Q3 2025.
  • Its 5-year average for Long-Term Investments is $848.0 million, with a median of $707.7 million in 2022.
  • In the last 5 years, Takeda Pharmaceutical's Long-Term Investments soared by 1651.11% in 2021 and then tumbled by 9692.09% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Long-Term Investments stood at $919.4 million in 2021, then fell by 27.3% to $668.4 million in 2022, then rose by 4.57% to $698.9 million in 2023, then tumbled by 88.06% to $83.5 million in 2024, then fell by 20.7% to $66.2 million in 2025.
  • Its Long-Term Investments stands at $66.2 million for Q4 2025, versus $60.5 million for Q3 2025 and $68.7 million for Q2 2025.